OX40 is a member of the TNF receptor superfamily expressed by activated T cells, and agonistic OX40 mAbs have direct stimulatory activities on effector T cells with the benefit of inhibiting Treg function in the tumor site, showing early promise in clinical trials (52). Here, TNFRSF4 is linked to neoplasm.